FDA 522 Applicability & Risk Calculator
This calculator helps regulatory, clinical, and quality teams estimate the practical likelihood that their device profile could attract stronger postmarket surveillance pressure under Section 522 of the FD&C Act. It is not a legal determination, but it creates a repeatable internal baseline for triage, budgeting, and provider selection.
Interactive Calculator
Run the calculator to view your preliminary risk tier and planning guidance.
How to Use This Output in Real Programs
Teams often make one of two mistakes when planning postmarket surveillance: they either dismiss the issue because there is no active order yet, or they jump into expensive provider conversations without a coherent assumption set. This calculator is designed to prevent both outcomes by forcing explicit assumptions at the start.
If your score lands in low pressure, you should still document why the score is low and what triggers a re-score. Practical triggers include adverse event pattern shifts, product architecture changes, new use environments, and materially different user populations. A score is only useful if your team also defines what would invalidate it.
If your score lands in medium pressure, that is usually the right time to prepare a light but structured pre-522 workstream: clarify endpoint vocabulary, tighten complaint coding quality, and map data sources that could support surveillance if needed. Medium pressure programs typically win by reducing response friction before any formal ask appears.
If your score lands in high pressure, your team should escalate quickly from conceptual planning to execution planning. High pressure does not always mean a future order is guaranteed, but it does mean your organization benefits from readiness artifacts now: site assumptions, monitoring plans, and budget scenarios aligned to realistic enrollment and follow-up constraints.
Why Section 522 Planning Is Often Underestimated
Section 522 planning sits at the intersection of regulatory strategy, clinical operations, and safety analytics. Because ownership spans multiple functions, accountability often diffuses across teams. Regulatory may assume clinical operations will define the operating model, while clinical operations may assume regulatory will provide endpoint and evidence framing. The result is delay and inconsistent quality.
A second challenge is timing uncertainty. Many organizations avoid structured preparation because they cannot predict if a postmarket surveillance request will arrive. That logic can appear financially conservative, but it often creates larger downstream costs. When readiness starts late, teams overpay for emergency provider mobilization, reactively rewrite protocols, and lose weeks in alignment cycles.
A third challenge is data realism. Sponsors frequently overestimate data cleanliness and underestimate operational effort required to transform routine quality and service records into surveillance-grade datasets. During execution, this gap surfaces as protocol friction, query burdens, and preventable delays in interim reporting. Early data mapping significantly reduces this risk.
These patterns are why a structured scoring model is useful: it creates a common language for cross-functional planning and a measurable threshold for when leadership should approve deeper preparation.
Detailed Interpretation Framework
Low Applicability Pressure
Low-pressure profiles usually combine mature technology, limited vulnerability in the intended population, no persistent safety signal trend, and moderate deployment scale. For these programs, the right strategy is disciplined monitoring rather than heavy pre-commitment spending. Maintain surveillance hygiene, maintain decision logs, and predefine escalation triggers. Do not confuse "low" with "zero."
Medium Applicability Pressure
Medium pressure often reflects mixed signals: perhaps technology is mostly mature but used in broader settings, or historical trend signals are weak but not absent. Medium profiles usually benefit from targeted investment in readiness: endpoint harmonization, data lineage mapping, and basic provider market scanning. The objective is to reduce organizational start-up time if surveillance needs intensify.
High Applicability Pressure
High pressure typically appears when risk factors stack: vulnerable populations, broad exposure, stronger signal trends, and meaningful novelty. For these programs, create a concrete 90-day readiness sprint that includes protocol architecture assumptions, enrollment feasibility checks, budget envelopes with contingencies, and executive governance cadence.
Operational Playbook: First 30, 60, and 90 Days
Days 0-30: Align stakeholders on assumptions and accountability. Define who owns clinical endpoints, who owns safety analytics, who owns provider engagement, and who signs off on budget assumptions. Build a data source inventory and classify each source by expected quality and accessibility.
Days 31-60: Pressure-test feasibility. Build at least two scenarios for enrollment and retention, one optimistic and one conservative. Draft a preliminary reporting calendar. Identify the most probable operational bottlenecks, then assign mitigation actions with owners and due dates.
Days 61-90: Convert planning into executable assets. Document protocol skeletons, monitoring plans, escalation criteria, and communication templates. If engaging external partners, compare providers using transparent assumptions rather than generic capabilities claims. This is where the directory page becomes useful: compare +50 providers using your own baseline, not vendor framing.
Common Failure Modes and How to Avoid Them
- Failure mode: weak endpoint clarity. Teams use broad endpoint language that cannot be measured consistently. Fix: define precise outcomes, data origin, timing, and adjudication approach.
- Failure mode: unowned data quality. Everyone assumes someone else cleans and reconciles key fields. Fix: assign named owners for source consistency, query turnaround, and audit trail completeness.
- Failure mode: budget optimism bias. Initial budgets exclude recruitment and retention friction. Fix: include conservative contingency assumptions from the start.
- Failure mode: reactive provider selection. Sponsors choose the first available provider under deadline pressure. Fix: maintain a pre-scored shortlist tied to your risk profile.
- Failure mode: poor escalation governance. Signal review meetings occur irregularly and decisions are not documented. Fix: establish recurring governance cadence with clear documentation standards.
EEAT Notes: Expertise, Experience, Authority, and Trust
Expertise: This content is structured for regulatory, clinical, quality, and safety teams that need practical implementation detail rather than generic definitions.
Experience: The scoring framework mirrors real decision friction points that appear in cross-functional device organizations: ownership ambiguity, delayed readiness, and budget under-specification.
Authority: Core references point to FDA and eCFR primary sources so teams can map planning assumptions to published regulatory frameworks.
Trust: The calculator clearly states its limits, avoids legal claims, and is designed as a planning aid that improves internal consistency before formal interactions.
Scenario Design: Build a Better Decision Envelope
A robust 522 planning process should define a decision envelope, not a single forecast. The decision envelope should include a low-disruption scenario, a likely scenario, and a high-disruption scenario. Each scenario should be tied to explicit assumptions and mapped to specific actions. This approach prevents teams from reacting emotionally to new data because the response path was already designed.
In the low-disruption scenario, your objective is lightweight control: maintain monitoring quality, preserve documentation discipline, and ensure trigger criteria are measurable. In the likely scenario, your objective is speed-to-readiness: prepare provider shortlists, align endpoint language, and pre-negotiate escalation mechanics. In the high-disruption scenario, your objective is execution certainty: allocate resources early, finalize governance cadence, and convert planning assumptions into operational artifacts.
Decision envelopes also improve leadership communication. Executives do not need perfect forecasts; they need confidence that the organization can respond predictably across plausible futures. A documented envelope gives that confidence because cost, timeline, and quality implications are visible in advance.
When teams skip envelope design, they tend to overfit planning to the most convenient scenario. That can look efficient in the short term but becomes expensive when field signals diverge from initial assumptions. A disciplined envelope is usually cheaper than reactive correction.
Implementation Checklist for Cross-Functional Teams
- Define one accountable owner for applicability scoring and one owner for score governance updates.
- Document input assumptions in plain language so cross-functional participants can challenge them effectively.
- Set recurring review cadence and mandatory re-score triggers tied to measurable indicators.
- Map score tiers to concrete actions, budgets, and provider engagement depth.
- Create an internal evidence register that tracks why scores changed and what actions followed.
This checklist sounds simple, but it addresses the most common failure pattern: organizations that collect data but fail to convert it into consistent decisions. Decision consistency, not data volume, is the core value driver in early 522 readiness work.
Teams that treat scoring as a one-time event lose most of its value. The score should function like a living control metric with governance ownership, version history, and explicit links to execution decisions. That structure gives regulators, leadership, and delivery teams a coherent narrative when assumptions evolve over time.
References
- [1] FDA, Postmarket Surveillance Under Section 522: https://www.fda.gov/medical-devices/postmarket-requirements-devices/postmarket-surveillance-under-section-522-federal-food-drug-and-cosmetic-act
- [2] eCFR, 21 CFR Part 822: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-822
- [3] FDA, MDR overview resources: https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems